Dornase alfa (rh DNase) is a recombinant human deoxyribonuclease produced using genetic engineering methods, it is the equivalent of a human enzyme that cleaves extracellular DNA.In vitro dornase alfa hydrolyzes DNA contained in sputum and significantly reduces sputum viscosity in cystic fibrosis. It is metabolized by proteases present in biological fluids. T0,5 is 3-4 hours.
Contraindications:
Hypersensitivity to the components of the preparation.
Precautions:
The amount of data for use in children under 5 years is limited. The decision on inclusion in the treatment of the preparation in children under 5 years should be taken by a center specialized in the treatment of cystic fibrosis, and therapy conducted under close supervision. To date, safety and efficacy have not been demonstrated in patients with FVC 40% below normal.
Pregnancy and lactation:
Caution should be exercised when using during pregnancy and breast-feeding.
Side effects:
Rare: chest pain (of pleural origin, non-cardiac origin), fever, conjunctivitis, indigestion, dysphonia, shortness of breath, pharyngitis, dyspnoea, laryngitis, rhinitis (all non-infectious), deterioration of lung function tests, rash, urticaria.
Dosage:
Adults and children over 5 years of age: 1 amp. 2,500 IU (2.5 mg) inhalation once a day using a nebulizer / nozzle compressor. In some patients over the age of 21 years, better results were achieved when taking the drug twice a day.
(C)
